Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.79 |
| ▸ | MAOB | P27338 | 5/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.79 |
| ▸ | SDHA | P31040 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | CALML3 | P27482 | 1/20 | 0.79 |
| ▸ | F10 | P00742 | 9/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167568 | 1.00 | MAOA (0.79) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6995056 | 0.91 | MAOB (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6995061 | 0.91 | MAOB (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6191297 | 0.91 | MAOB (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6191303 | 0.91 | MAOB (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6991516 | 0.91 | MAOB (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6991510 | 0.91 | MAOB (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6992074 | 0.90 | MAOB (0.79) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6992080 | 0.90 | MAOB (0.79) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6988314 | 0.90 | MAOB (0.78) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0750618-B1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2003-02-19 | — | — | EP | claimed |
| EP-0750618-A1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-02 | — | — | EP | claimed |
| WO-1995025106-A1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1995-09-21 | — | — | WO | claimed |
| US-20090018123-A1 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation | SINDKHEDKAR MILIND D | 2009-01-15 | — | — | US | disclosed |
| EP-1912980-A2 | OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION | Wockhardt Limited (IN) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007023507-A2 | OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION | WOCKHARDT LIMITED (IN) | 2007-03-01 | — | — | WO | disclosed |
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-02 | — | — | US | disclosed |
| EP-1409464-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2004-04-21 | — | — | EP | disclosed |
| EP-1019385-B1 | AMINOARYL OXAZOLIDINONE N-OXIDES | UPJOHN CO (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6525193-B2 | Bactericides | PHARMACIA & UPJOHN COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-0750618-B1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2003-02-19 | — | — | EP | disclosed |
| US-6441188-B1 | SUCH AS (S)-N-((3-(3-FLUORO-4-(1,1-DIOXOTHIAZOLIDIN-3-YL) PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)ACETAMIDE N-OXIDE FOR TREATMENT OF MICROBIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020107402-A1 | Aminoaryl oxazolidinone N-oxides | GADWOOD ROBERT C (US) | 2002-08-08 | — | — | US | disclosed |
| US-20010051722-A1 | Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria | GADWOOD ROBERT C (US) | 2001-12-13 | — | — | US | disclosed |
| US-6277985-B1 | AS ANTIBIOTICS; WATER SOLUBILITY; IN PRODRUGS | PHARMACIA & UPJOHN COMPANY | 2001-08-21 | — | — | US | disclosed |
| EP-1019385-A1 | AMINOARYL OXAZOLIDINONE N-OXIDES | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5668286-A | ANTIBIOTIC | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997010223-A1 | AMINOARYL OXAZOLIDINONE N-OXIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-20 | — | — | WO | disclosed |
| EP-0750618-A1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025106-A1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | PDK4, OXA1L, PPARD | MAOA 1955/4885MAOB 1961/4885PTGS1 2918/4885 |
| US-20010051722-A1 | Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria | AMD1, CYP11B1, ALDH7A1 | MAOA 289/4885MAOB 180/4885PTGS1 2076/4885 |
| US-20020107402-A1 | Aminoaryl oxazolidinone N-oxides | CYP11B1, ABAT, MSMO1 | MAOA 331/4885MAOB 190/4885PTGS1 2067/4885 |
| US-20090018123-A1 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation | POLL, POLM, POLRMT | MAOA 3788/4885MAOB 3240/4885PTGS1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.